» Articles » PMID: 20035430

Antibodies and Neuronal Autoimmune Disorders of the CNS

Overview
Journal J Neurol
Specialty Neurology
Date 2009 Dec 26
PMID 20035430
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

We review the neuronal antibodies described in CNS disorders in order to clarify their diagnostic value, emphasize potentials pitfalls and limitations in the diagnosis of paraneoplastic neurological syndromes (PNS), and examine the current evidence for a possible pathogenic role. We propose to classify the neuronal antibodies associated with syndromes resulting from CNS neuronal dysfunction into two groups according to the location of the antigen: inside the neuron or in the cell membrane. Group I includes antibodies which target intracellular antigens and probably are not pathogenic. They are further subdivided into three groups. Group Ia comprises well-characterized onconeural antibodies (Hu (ANNA1), Yo (PCA1), Ri (ANNA2), CV2 (CRMP5), amphiphysin, Ma2) that are useful for the diagnosis of PNS. Group Ib antibodies (SOX and ZIC) are cancer-specific but there is no evidence that the immune response is in any way pathogenically related to the PNS. Antibodies in group Ic (glutamic acid decarboxylase (GAD), adenylate kinase 5 and Homer 3) identify non-PNS: stiff-person syndrome (SPS), cerebellar ataxia, and limbic encephalitis (LE). Group II antibodies recognize neuronal surface antigens. Antibodies in group IIa associate with characteristic CNS syndromes but their detection does not indicate that the disorder is paraneoplastic. Antibodies to potassium channels, AMPA and GABA(B) receptors are associated with LE, NMDA receptor antibodies identify a well-defined encephalitis, and antibodies against glycine receptors associate with SPS with encephalitis. A pathogenic role of the antibodies is suggested by the response of symptoms to immunotherapy and the correlation between antibody titers and neurological outcome. Lastly, Group IIb includes antibodies that are found in patients with paraneoplastic cerebellar ataxia associated with lung cancer (P/Q type calcium channels antibodies) or Hodgkin disease (metabotropic glutamate receptor type 1 antibodies).

Citing Articles

Clinical Features of Glutamic Acid Decarboxylase-65 Neurological Autoimmunity: A Case Series From China.

Qiu Z, Xu F, Zhang M, Yang X, Han Y, Li D CNS Neurosci Ther. 2025; 31(2):e70237.

PMID: 39976255 PMC: 11840705. DOI: 10.1111/cns.70237.


Impact of Experimental Congenital Toxoplasmosis on the Thyroid Gland: Histopathological and Immunobiochemical Indices Assessment.

Elgawad H, Elmehankar M, Nabih N, Sheta H, Awad S Acta Parasitol. 2025; 70(1):43.

PMID: 39853582 PMC: 11761858. DOI: 10.1007/s11686-024-00969-x.


The role of the adenylate kinase 5 gene in various diseases and cancer.

Siddiqui M, Shahi M, Castresana J J Clin Transl Sci. 2024; 8(1):e96.

PMID: 39655021 PMC: 11626602. DOI: 10.1017/cts.2024.536.


Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms.

Mitoma H, Manto M J Neurol. 2024; 271(10):7046-7053.

PMID: 39052041 DOI: 10.1007/s00415-024-12596-7.


Anti-GAD Encephalitis Following COVID-19 Vaccination: A Case Report.

Deniz C, Altunan B, Unal A Noro Psikiyatr Ars. 2023; 60(3):283-287.

PMID: 37645084 PMC: 10461762. DOI: 10.29399/npa.28251.


References
1.
Honnorat J, Antoine J, Derrington E, Aguera M, Belin M . Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 1996; 61(3):270-8. PMC: 486550. DOI: 10.1136/jnnp.61.3.270. View

2.
Vernino S, Tuite P, Adler C, Meschia J, Boeve B, Boasberg P . Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol. 2002; 51(5):625-30. DOI: 10.1002/ana.10178. View

3.
Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, De Andres C . Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol. 2001; 58(2):225-30. DOI: 10.1001/archneur.58.2.225. View

4.
Tan K, Lennon V, Klein C, Boeve B, Pittock S . Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology. 2008; 70(20):1883-90. DOI: 10.1212/01.wnl.0000312275.04260.a0. View

5.
Sabater L, Bataller L, Suarez-Calvet M, Saiz A, Dalmau J, Graus F . ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol. 2008; 201-202:163-5. PMC: 2582201. DOI: 10.1016/j.jneuroim.2008.01.018. View